Inicio › Linfoma difuso de células B grandes › California

Ensayos clínicos de Linfoma difuso de células B grandes en California

43 estudios sobre Linfoma difuso de células B grandes buscan participantes en California.

Ciudades en California

Texto oficial del estudio (inglés)

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Cedars-Sinai Medical Center, Los Angeles

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06649812

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05006716

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135), Burbank
City of Hope Comprehensive Cancer Center ( Site 0191), Duarte
Bass Medical Group ( Site 0123), Walnut Creek

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06890884

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Bass Medical Group ( Site 0166), Walnut Creek

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05139017

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Providence Medical Foundation-Oncology ( Site 0168), Fullerton
MemorialCare Health System - Long Beach Medical Center ( Site 9559), Long Beach
Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06717347

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles
University of California Irvine Medical Center, Orange
UC Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06091865

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

City of Hope, Duarte
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07101328

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

ReclutandoFase 1/2

6 Months – 25 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT06395103

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

City of Hope Medical Center, Duarte
University of California San Diego Medical Center, Moores Cancer Center, La Jolla

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07195916

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Community Cancer Institute (CCI), Clovis
Providence Medical Foundation, Fullerton
Los Angeles Cancer Network, Glendale
y 4 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06806033

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

City of Hope Comprehensive Cancer Center, Duarte
University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT05272384

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Alta Bates Summit Medical Center, Berkeley
City of Hope, Duarte
Cedars-Sinai Medical Center, Los Angeles
y 4 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT06500273

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center, Duarte

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07365306

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center, Irvine
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles (UCLA) Medical Center, Los Angeles
y 1 más

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

ReclutandoFase 1

Edades de 18 a 85 · Todos los sexos · Actualizado el 10 ago 2026 · NCT05887167

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Stanford University, Stanford

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles (UCLA), Los Angeles
University of California, Irvine, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558

A Long-term Extension Study of PCI-32765 (Ibrutinib)

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT01804686

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jul 2026 · NCT07424833

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jul 2026 · NCT05052528

DALY II USA/ MB-CART2019.1 for DLBCL

UC San Diego Health, La Jolla
Stanford University, Stanford

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

City of Hope Comprehensive Cancer Center, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT05077527

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center, Duarte

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT05672251

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Comprehensive Cancer Center, Duarte
University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 jul 2026 · NCT06015880

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jul 2026 · NCT06854159

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jun 2026 · NCT06905509

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jun 2026 · NCT04545762

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 abr 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
y 1 más

ReclutandoFase 1/2

Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT04830137

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoFase 1/2

Edades de 18 a 70 · Todos los sexos · Actualizado el 10 mar 2026 · NCT05256641

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

City of Hope Medical Center, Duarte

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 mar 2026 · NCT07042438

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 feb 2026 · NCT05432635

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

City of Hope Medical Center, Duarte

ReclutandoFase 1 temprana

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 feb 2026 · NCT05800405

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

UC Irvine Health Cancer Center-Newport, Costa Mesa
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UCI Health Laguna Hills, Laguna Hills
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 feb 2026 · NCT05633615

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Tower Cancer Research Foundation, Beverly Hills
City of Hope Comprehensive Cancer Center, Duarte
City of Hope Seacliff, Huntington Beach
y 7 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2025 · NCT05890352

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.